{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T12:02:20Z","timestamp":1793016140677,"version":"4.5.0"},"reference-count":69,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Trends in Cardiovascular Medicine"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.tcm.2025.01.001","type":"journal-article","created":{"date-parts":[[2025,1,21]],"date-time":"2025-01-21T03:38:26Z","timestamp":1737430706000},"page":"258-265","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"title":["Metabolic dysfunction-associated steatotic liver disease and the cardiovascular system"],"prefix":"10.1016","volume":"35","author":[{"given":"Antonis A.","family":"Manolis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theodora A.","family":"Manolis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Apostolos","family":"Vouliotis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0336-4745","authenticated-orcid":false,"given":"Antonis S.","family":"Manolis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.tcm.2025.01.001_bib0001","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1186\/s12933-024-02434-5","article-title":"Metabolic dysfunction-associated steatotic liver disease and cardiovascular risk: a comprehensive review","volume":"23","author":"Zheng","year":"2024","journal-title":"Cardiovasc Diabetol"},{"issue":"1","key":"10.1016\/j.tcm.2025.01.001_bib0002","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/hep.28431","article-title":"Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes","volume":"64","author":"Younossi","year":"2016","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.tcm.2025.01.001_bib0003","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/j.jhep.2012.12.005","article-title":"The burden of liver disease in Europe: a review of available epidemiological data","volume":"58","author":"Blachier","year":"2013","journal-title":"J Hepatol"},{"issue":"5","key":"10.1016\/j.tcm.2025.01.001_bib0004","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1007\/s12325-020-01307-z","article-title":"Direct Oral anticoagulants in patients with liver disease in the era of non-alcoholic fatty liver disease global epidemic: a narrative review","volume":"37","author":"Ballestri","year":"2020","journal-title":"Adv Ther"},{"issue":"11","key":"10.1016\/j.tcm.2025.01.001_bib0005","doi-asserted-by":"crossref","first-page":"2939","DOI":"10.1111\/liv.16075","article-title":"Clinical outcomes of MAFLD versus NAFLD: a meta-analysis of observational studies","volume":"44","author":"Pennisi","year":"2024","journal-title":"Liver Int"},{"issue":"1","key":"10.1016\/j.tcm.2025.01.001_bib0006","doi-asserted-by":"crossref","first-page":"S47","DOI":"10.1016\/j.jhep.2014.12.012","article-title":"NAFLD: a multisystem disease","volume":"62","author":"Byrne","year":"2015","journal-title":"J Hepatol"},{"issue":"5","key":"10.1016\/j.tcm.2025.01.001_bib0007","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1097\/HEP.0000000000000323","article-title":"AASLD practice guidance on the clinical assessment and management of nonalcoholic fatty liver disease","volume":"77","author":"Rinella","year":"2023","journal-title":"Hepatology"},{"issue":"8","key":"10.1016\/j.tcm.2025.01.001_bib0008","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0309617","article-title":"Cardiovascular risk in US adults with nonalcoholic steatohepatitis (NASH) vs. matched non-NASH controls, National health and nutrition examination survey, 2017-2020","volume":"19","author":"Woolley","year":"2024","journal-title":"PLoS One"},{"issue":"10464","key":"10.1016\/j.tcm.2025.01.001_bib0009","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1016\/S0140-6736(24)01811-7","article-title":"Steatotic liver disease","volume":"404","author":"Israelsen","year":"2024","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.tcm.2025.01.001_bib0010","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1016\/j.jhep.2023.05.046","article-title":"Liver disease is a significant risk factor for cardiovascular outcomes - A UK Biobank study","volume":"79","author":"Roca-Fernandez","year":"2023","journal-title":"J Hepatol"},{"issue":"7","key":"10.1016\/j.tcm.2025.01.001_bib0011","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/j.amjmed.2023.03.010","article-title":"Cardiovascular disease risk and statin use among adults with metabolic dysfunction associated fatty liver disease","volume":"136","author":"Yeoh","year":"2023","journal-title":"Am J Med"},{"issue":"9","key":"10.1016\/j.tcm.2025.01.001_bib0012","doi-asserted-by":"crossref","first-page":"344","DOI":"10.31083\/j.rcm2509344","article-title":"Non-invasive serum markers of non-alcoholic fatty liver disease fibrosis: potential tools for detecting patients with cardiovascular disease","volume":"25","author":"Chen","year":"2024","journal-title":"Rev Cardiovasc Med"},{"issue":"9","key":"10.1016\/j.tcm.2025.01.001_bib0013","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1136\/gutjnl-2021-325724","article-title":"Non-alcoholic fatty liver disease and incident major adverse cardiovascular events: results from a nationwide histology cohort","volume":"71","author":"Simon","year":"2022","journal-title":"Gut"},{"key":"10.1016\/j.tcm.2025.01.001_bib0014","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1136\/gutjnl-2022-327672","article-title":"Non-alcoholic fatty liver disease and risk of new-onset heart failure: an updated meta-analysis of about 11 million individuals","volume":"72","author":"Mantovani","year":"2023","journal-title":"Gut"},{"issue":"11","key":"10.1016\/j.tcm.2025.01.001_bib0015","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1038\/s41575-023-00800-4","article-title":"Lifestyle interventions in nonalcoholic fatty liver disease","volume":"20","author":"Younossi","year":"2023","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"10","key":"10.1016\/j.tcm.2025.01.001_bib0016","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1016\/j.cgh.2024.03.006","article-title":"The global epidemiology of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among patients with type 2 diabetes","volume":"22","author":"Younossi","year":"2024","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"11","key":"10.1016\/j.tcm.2025.01.001_bib0017","doi-asserted-by":"crossref","first-page":"2138","DOI":"10.1136\/gutjnl-2023-330110","article-title":"Global prevalence of non-alcoholic fatty liver disease in type 2 diabetes mellitus: an updated systematic review and meta-analysis","volume":"72","author":"En","year":"2023","journal-title":"Gut"},{"issue":"1","key":"10.1016\/j.tcm.2025.01.001_bib0018","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/S2468-1253(22)00317-X","article-title":"Global prevalence of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in the overweight and obese population: a systematic review and meta-analysis","volume":"8","author":"Quek","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"12","key":"10.1016\/j.tcm.2025.01.001_bib0019","doi-asserted-by":"crossref","first-page":"3624","DOI":"10.1038\/s41591-024-03283-1","article-title":"Data-driven cluster analysis identifies distinct types of metabolic dysfunction-associated steatotic liver disease","volume":"30","author":"Raverdy","year":"2024","journal-title":"Nat Med"},{"issue":"12","key":"10.1016\/j.tcm.2025.01.001_bib0020","doi-asserted-by":"crossref","first-page":"3614","DOI":"10.1038\/s41591-024-03284-0","article-title":"Partitioned polygenic risk scores identify distinct types of metabolic dysfunction-associated steatotic liver disease","volume":"30","author":"Jamialahmadi","year":"2024","journal-title":"Nat Med"},{"issue":"11","key":"10.1016\/j.tcm.2025.01.001_bib0021","doi-asserted-by":"crossref","first-page":"3045","DOI":"10.1016\/j.jtha.2023.06.017","article-title":"The prothrombotic tendency of metabolic-associated fatty liver disease","volume":"21","author":"Swan","year":"2023","journal-title":"J Thromb Haemost"},{"issue":"1","key":"10.1016\/j.tcm.2025.01.001_bib0022","doi-asserted-by":"crossref","first-page":"79","DOI":"10.4254\/wjh.v15.i1.79","article-title":"Influence of non-alcoholic fatty liver disease on non-variceal upper gastrointestinal bleeding: a nationwide analysis","volume":"15","author":"Soni","year":"2023","journal-title":"World J Hepatol"},{"issue":"19","key":"10.1016\/j.tcm.2025.01.001_bib0023","doi-asserted-by":"crossref","first-page":"10595","DOI":"10.3390\/ijms251910595","article-title":"Non-alcoholic fatty liver disease and coronary artery disease: a bidirectional association based on endothelial dysfunction","volume":"25","author":"Ktenopoulos","year":"2024","journal-title":"Int J Mol Sci"},{"issue":"11","key":"10.1016\/j.tcm.2025.01.001_bib0024","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.1016\/j.cgh.2021.09.021","article-title":"A meta-analysis on the global prevalence, risk factors and screening of coronary heart disease in nonalcoholic fatty liver disease","volume":"20","author":"Toh","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"10","key":"10.1016\/j.tcm.2025.01.001_bib0025","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1055\/a-2266-1503","article-title":"The Pathophysiological associations between obesity, NAFLD, and atherosclerotic cardiovascular diseases","volume":"56","author":"Li","year":"2024","journal-title":"Horm Metab Res"},{"issue":"9","key":"10.1016\/j.tcm.2025.01.001_bib0026","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1111\/apt.17424","article-title":"Higher mortality among lean patients with non-alcoholic fatty liver disease despite fewer metabolic comorbidities","volume":"57","author":"Wijarnpreecha","year":"2023","journal-title":"Aliment Pharmacol Ther"},{"issue":"5","key":"10.1016\/j.tcm.2025.01.001_bib0027","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1007\/s12072-024-10716-z","article-title":"Liver and cardiovascular outcomes in lean non-alcoholic fatty liver disease: an updated systematic review and meta-analysis of about 1 million individuals","volume":"18","author":"Souza","year":"2024","journal-title":"Hepatol Int"},{"issue":"11","key":"10.1016\/j.tcm.2025.01.001_bib0028","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1161\/CIRCRESAHA.120.316101","article-title":"Obesity phenotypes, diabetes, and cardiovascular diseases","volume":"126","author":"Pich\u00e9","year":"2020","journal-title":"Circ Res"},{"issue":"6","key":"10.1016\/j.tcm.2025.01.001_bib0029","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1097\/MCO.0000000000000317","article-title":"but not healthy: the 'metabolically obese, normal-weight' phenotype","volume":"19","author":"Ding","year":"2016","journal-title":"Curr Opin Clin Nutr Metab Care"},{"issue":"3","key":"10.1016\/j.tcm.2025.01.001_bib0030","doi-asserted-by":"crossref","first-page":"348","DOI":"10.15403\/jgld-5533","article-title":"The relationship between liver fibrosis scores and ascending aortic dilatation","volume":"33","author":"Duman","year":"2024","journal-title":"J Gastrointestin Liver Dis"},{"issue":"6","key":"10.1016\/j.tcm.2025.01.001_bib0031","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1161\/CIRCULATIONAHA.122.062874","article-title":"Cardiometabolic hfpef: nash of the heart","volume":"147","author":"Capone","year":"2023","journal-title":"Circulation"},{"issue":"3","key":"10.1016\/j.tcm.2025.01.001_bib0032","first-page":"194","article-title":"Pathophysiological mechanisms of cardiovascular disorders in non-alcoholic fatty liver disease","volume":"15","author":"Garbuzenko","year":"2022","journal-title":"Gastroenterol Hepatol Bed Bench"},{"issue":"8","key":"10.1016\/j.tcm.2025.01.001_bib0033","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0136822","article-title":"Dysregulated hepatic methionine metabolism drives homocysteine elevation in diet-induced nonalcoholic fatty liver disease","volume":"10","author":"Pacana","year":"2015","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.tcm.2025.01.001_bib0034","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.jhep.2016.04.005","article-title":"Non-alcoholic fatty liver disease and cardiovascular risk: pathophysiological mechanisms and implications","volume":"65","author":"Francque","year":"2016","journal-title":"J Hepatol"},{"key":"10.1016\/j.tcm.2025.01.001_bib0035","doi-asserted-by":"crossref","DOI":"10.1155\/2020\/1825142","article-title":"Endothelial dysfunction, a marker of atherosclerosis, is independent of metabolic syndrome in NAFLD patients","volume":"2020","author":"Narayan","year":"2020","journal-title":"Int J Hepatol"},{"issue":"7","key":"10.1016\/j.tcm.2025.01.001_bib0036","first-page":"534","article-title":"Non-alcoholic fatty liver disease-From the cardiologist perspective","volume":"16","author":"S\u00eerbu","year":"2016","journal-title":"Anatol J Cardiol"},{"key":"10.1016\/j.tcm.2025.01.001_bib0037","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.ejim.2023.11.005","article-title":"Natural history of metabolic dysfunction-associated steatotic liver disease","volume":"122","author":"Lekakis","year":"2024","journal-title":"Eur J Intern Med"},{"issue":"11","key":"10.1016\/j.tcm.2025.01.001_bib0038","doi-asserted-by":"crossref","first-page":"4335","DOI":"10.1007\/s12325-024-02979-7","article-title":"Progression from non-alcoholic steatohepatitis to advanced liver diseases and mortality among medicare patients","volume":"41","author":"Kim","year":"2024","journal-title":"Adv Ther"},{"issue":"4","key":"10.1016\/j.tcm.2025.01.001_bib0039","first-page":"691","article-title":"MASLD: a systemic metabolic disorder with cardiovascular and malignant complications","volume":"73","author":"Targher","year":"2024","journal-title":"Gut"},{"issue":"2","key":"10.1016\/j.tcm.2025.01.001_bib0040","doi-asserted-by":"crossref","first-page":"235","DOI":"10.3350\/cmh.2023.0485","article-title":"Global incidence of adverse clinical events in non-alcoholic fatty liver disease: a systematic review and meta-analysis","volume":"30","author":"Le","year":"2024","journal-title":"Clin Mol Hepatol"},{"issue":"2","key":"10.1016\/j.tcm.2025.01.001_bib0041","doi-asserted-by":"crossref","DOI":"10.1016\/j.aohep.2024.101589","article-title":"Prevalence and risk factors of significant fibrosis in chronic hepatitis B patients with concurrent metabolic dysfunction-associated steatotic liver disease","volume":"30","author":"Hong","year":"2024","journal-title":"Ann Hepatol"},{"issue":"15","key":"10.1016\/j.tcm.2025.01.001_bib0042","doi-asserted-by":"crossref","first-page":"e35453","DOI":"10.1016\/j.heliyon.2024.e35453","article-title":"Comprehensive analysis of shared risk genes and immunity-metabolisms between non-alcoholic fatty liver disease and atherosclerosis via bulk and single-cell transcriptome analyses","volume":"10","author":"Hu","year":"2024","journal-title":"Heliyon"},{"key":"10.1016\/j.tcm.2025.01.001_bib0043","doi-asserted-by":"crossref","first-page":"zwae336","DOI":"10.1093\/eurjpc\/zwae336","article-title":"The association between non-alcohol liver fatty disease and coronary artery calcification: a two-sample mendelian randomization study","author":"He","year":"2024","journal-title":"Eur J Prev Cardiol"},{"issue":"9","key":"10.1016\/j.tcm.2025.01.001_bib0044","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1158\/1055-9965.EPI-23-0453","article-title":"Genetic susceptibility to nonalcoholic fatty liver disease and risk for pancreatic cancer: mendelian randomization","volume":"32","author":"King","year":"2023","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"11","key":"10.1016\/j.tcm.2025.01.001_bib0045","doi-asserted-by":"crossref","first-page":"2177","DOI":"10.1016\/j.cgh.2024.05.052","article-title":"Genetics of metabolic dysfunction-associated steatotic liver disease: the state of the art update","volume":"22","author":"Sookoian","year":"2024","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"10","key":"10.1016\/j.tcm.2025.01.001_bib0046","doi-asserted-by":"crossref","first-page":"2266","DOI":"10.3390\/nu15102266","article-title":"Ultra-processed food intake is associated with non-alcoholic fatty liver disease in adults: a systematic review and meta-analysis","volume":"15","author":"Henney","year":"2023","journal-title":"Nutrients"},{"issue":"1","key":"10.1016\/j.tcm.2025.01.001_bib0047","first-page":"201","article-title":"Prevalence of chronic kidney disease in nonalcoholic fatty liver disease patients","volume":"33","author":"Elgakhow","year":"2022","journal-title":"Saudi J Kidney Dis Transpl"},{"issue":"5","key":"10.1016\/j.tcm.2025.01.001_bib0048","doi-asserted-by":"crossref","first-page":"541","DOI":"10.3892\/ol.2024.14674","article-title":"Advances in the study of the mechanism of action of miR\u201122 in liver lesions (Review)","volume":"28","author":"Wang","year":"2024","journal-title":"Oncol Lett"},{"key":"10.1016\/j.tcm.2025.01.001_bib0049","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2022.101581","article-title":"MicroRNAs in non-alcoholic fatty liver disease: progress and perspectives","volume":"65","author":"Hochreuter","year":"2022","journal-title":"Mol Metab"},{"issue":"2","key":"10.1016\/j.tcm.2025.01.001_bib0050","doi-asserted-by":"crossref","first-page":"C588","DOI":"10.1152\/ajpcell.00253.2022","article-title":"Circulating miRNAs associated with nonalcoholic fatty liver disease","volume":"324","author":"Atic","year":"2023","journal-title":"Am J Physiol Cell Physiol"},{"key":"10.1016\/j.tcm.2025.01.001_bib0051","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1007\/978-3-031-63657-8_18","article-title":"Nonalcoholic fatty liver disease and staging of hepatic fibrosis","volume":"1460","author":"Engin","year":"2024","journal-title":"Adv Exp Med Biol"},{"issue":"1","key":"10.1016\/j.tcm.2025.01.001_bib0052","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1161\/CIRCULATIONAHA.124.070535","article-title":"Cardiovascular-liver-metabolic health: recommendations in screening, diagnosis, and management of metabolic dysfunction-associated steatotic liver disease in cardiovascular disease via modified delphi approach","volume":"151","author":"Chew","year":"2025","journal-title":"Circulation"},{"issue":"7","key":"10.1016\/j.tcm.2025.01.001_bib0053","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/S2468-1253(23)00066-3","article-title":"Non-invasive diagnosis and monitoring of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis","volume":"8","author":"Tincopa","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"6","key":"10.1016\/j.tcm.2025.01.001_bib0054","doi-asserted-by":"crossref","first-page":"660","DOI":"10.23736\/S0026-4806.24.09290-5","article-title":"Noninvasive tools for the assessment of fibrosis in metabolic dysfunction-associated steatotic liver disease","volume":"115","author":"Rigor","year":"2024","journal-title":"Minerva Med"},{"issue":"1","key":"10.1016\/j.tcm.2025.01.001_bib0055","doi-asserted-by":"crossref","first-page":"66","DOI":"10.3390\/nu15010066","article-title":"The FIB-4 index predicts the development of liver-related events, extrahepatic cancers, and coronary vascular disease in patients with NAFLD","volume":"15","author":"Kamada","year":"2022","journal-title":"Nutrients"},{"key":"10.1016\/j.tcm.2025.01.001_bib0056","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2024.1433857","article-title":"Systemic impacts of metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH) on heart, muscle, and kidney related diseases","volume":"12","author":"Sandireddy","year":"2024","journal-title":"Front Cell Dev Biol"},{"key":"10.1016\/j.tcm.2025.01.001_bib0057","first-page":"S0021","article-title":"Prevalence of fatty pancreas and its relation with anthropometric values on the growth and obesity cohort study","author":"Alberti","year":"2024","journal-title":"J Pediatr (Rio J)"},{"issue":"23","key":"10.1016\/j.tcm.2025.01.001_bib0058","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.123.031440","article-title":"Associations of unhealthy lifestyle and nonalcoholic fatty liver disease with cardiovascular healthy outcomes","volume":"12","author":"Wu","year":"2023","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.tcm.2025.01.001_bib0059","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.ejim.2023.11.012","article-title":"Management of cardiovascular risk in patients with metabolic dysfunction-associated steatotic liver disease","volume":"122","author":"Mellemkj\u00e6r","year":"2024","journal-title":"Eur J Intern Med"},{"issue":"10","key":"10.1016\/j.tcm.2025.01.001_bib0060","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1016\/j.clnu.2022.08.001","article-title":"Statins' efficacy in non-alcoholic fatty liver disease: a systematic review and meta-analysis","volume":"41","author":"Boutari","year":"2022","journal-title":"Clin Nutr"},{"issue":"12","key":"10.1016\/j.tcm.2025.01.001_bib0061","doi-asserted-by":"crossref","first-page":"5713","DOI":"10.1002\/ptr.8347","article-title":"Silybin: a review of its targeted and novel agents for treating liver diseases based on pathogenesis","volume":"38","author":"Wu","year":"2024","journal-title":"Phytother Res"},{"issue":"8","key":"10.1016\/j.tcm.2025.01.001_bib0062","first-page":"e67083","article-title":"Silymarin as an antioxidant therapy in chronic liver diseases: a comprehensive review","volume":"16","author":"Dhande","year":"2024","journal-title":"Cureus"},{"issue":"8","key":"10.1016\/j.tcm.2025.01.001_bib0063","first-page":"e67080","article-title":"Mechanisms of non-alcoholic fatty liver disease and beneficial effects of semaglutide: a review","volume":"16","author":"Alfawaz","year":"2024","journal-title":"Cureus"},{"issue":"11\u201312","key":"10.1016\/j.tcm.2025.01.001_bib0064","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1111\/apt.18331","article-title":"Semaglutide 2.4\u2009mg in participants with metabolic dysfunction-associated steatohepatitis: baseline characteristics and design of the phase 3 essence trial","volume":"60","author":"Newsome","year":"2024","journal-title":"Aliment Pharmacol Ther"},{"issue":"8","key":"10.1016\/j.tcm.2025.01.001_bib0065","first-page":"e43635","article-title":"Vitamin E and pioglitazone: a comprehensive systematic review of their efficacy in non-alcoholic fatty liver disease","volume":"15","author":"Mazhar","year":"2023","journal-title":"Cureus"},{"issue":"3","key":"10.1016\/j.tcm.2025.01.001_bib0066","first-page":"313","article-title":"Resmetirom (rezdiffra) for the treatment of noncirrhotic nonalcoholic steatohepatitis with moderate to advanced fibrosis","volume":"110","author":"Ohri","year":"2024","journal-title":"Am Fam Physician"},{"key":"10.1016\/j.tcm.2025.01.001_bib0067","doi-asserted-by":"crossref","unstructured":"EASL-EASD-EASO Clinical practice guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD): executive summary. Diabetologia 2024; 67(11):2375\u201392.","DOI":"10.1007\/s00125-024-06196-3"},{"issue":"1","key":"10.1016\/j.tcm.2025.01.001_bib0068","doi-asserted-by":"crossref","first-page":"23999","DOI":"10.1038\/s41598-024-74791-w","article-title":"The correlation between Life's essential 8 and cardiovascular disease and mortality in individuals with nonalcoholic fatty liver disease: a cross-sectional study","volume":"14","author":"Sun","year":"2024","journal-title":"Sci Rep"},{"key":"10.1016\/j.tcm.2025.01.001_bib0069","doi-asserted-by":"crossref","first-page":"e64","DOI":"10.15420\/ecr.2023.22","article-title":"Clinical management of non-alcoholic steatohepatitis and the role of the cardiologist","volume":"18","author":"Mill\u00e1n-Rodr\u00edguez","year":"2023","journal-title":"Eur Cardiol"}],"container-title":["Trends in Cardiovascular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1050173825000064?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1050173825000064?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,3]],"date-time":"2025-05-03T15:06:01Z","timestamp":1746284761000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1050173825000064"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":69,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["S1050173825000064"],"URL":"https:\/\/doi.org\/10.1016\/j.tcm.2025.01.001","relation":{},"ISSN":["1050-1738"],"issn-type":[{"value":"1050-1738","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Metabolic dysfunction-associated steatotic liver disease and the cardiovascular system","name":"articletitle","label":"Article Title"},{"value":"Trends in Cardiovascular Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tcm.2025.01.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}